Decision Resources, Inc., one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, has defined a hypothetical Parkinson's disease drug that surveyed neurologists say they would prescribe to 25% of their Parkinson's disease patients. According to the new report entitled "Parkinson's Disease: Turning Physician Insight into Projected Patient Share", a transdermal dopamine agonist would earn 25% patient share in early Parkinson's disease even if its only advantages over sales-leader Boehringer Ingelheim's Mirapex are a minor reduction in nausea, once-daily dosing, and a 20% lower price.

"Developers of Parkinson's disease drugs have worked on realistic targets including novel formulations of agents with proven mechanisms of action. Presumably, these formulations will offer only an incremental improvement in convenience-a once-daily patch application versus the three- to four-times daily dosing of currently available dopamine agonists," said Julie Kerner, Ph.D., analyst at Decision Resources. "Our research reveals that there is room in the Parkinson's disease market for these reformulations."

About "Parkinson's Disease: Turning Physician Insight into Projected Patient Share"

"Parkinson's Disease: Turning Physician Insight into Projected Patient Share" covers the current and future state of the Parkinson's disease drug market. The report includes:

   -- More than 3,000 physician responses that define drug attributes that       drive prescription now and in the future.         -- Clinical end point tradeoffs that are most influential to            physicians.         -- Areas of unmet need with highest potential.         -- Benchmark trial results for specific drug opportunities.         -- Patient share potential for emerging therapies and target product            profiles.    -- Decision Resources proprietary analysis of commercial factors that       accelerate or constrain a drug's market potential.         -- Promotion: DTC spend, detailing intensity.         -- Reimbursement: formulary tier, prior approval restriction,            quantity limits.         -- Labeling: black box warnings, approved patient segments,            contraindications.         -- Competition: order of entry, pricing, generic entry, pipeline            sales forecast.         -- Medical practice: decision trees, treating physician type, line            of therapy.    -- Comparisons of the key clinical attributes of current and emerging       therapies in the areas of efficacy, safety, and delivery.    -- Analysis and supporting data that identifies the clinical "Gold       Standard" now and over the next ten years.    -- Key insights as to which clinical end points have the greatest       influence on physician decision-making.  

The report can be purchased by contacting Decision Resources. Members of the media may request a complimentary copy or an interview with an analyst.

About Decision Resources

Decision Resources, Inc., (www.decisionresources.com) is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

  For more information, contact:   Elizabeth Marshall   Decision Resources, Inc.   781-296-2563   emarshall@dresources.com 

SOURCE: Decision Resources, Inc.

CONTACT: Elizabeth Marshall of Decision Resources, Inc.,
+1-781-296-2563, or emarshall@dresources.com

Surveyed HIV Specialists Say That a Novel Integrase Inhibitor Could Potentially Capture More Than 20% of the HIV Market

View Now